Which has the lower trailing P/E, BMRN or GMED?

GMED has the lower trailing P/E: BMRN trades at 147.54 and GMED at 19.68. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BMRN or GMED?

Over the past five years, GMED grew revenue faster — BMRN at a 12.19% CAGR versus GMED at 27.65%.

Is BMRN or GMED more profitable?

GMED runs the higher net margin — BMRN at 2.14% versus GMED at 17.03%.

How have BMRN and GMED total returns compared?

Over the past 10 years, BMRN delivered -4.98% and GMED delivered 12.82% annualized total return. Past performance doesn't predict future results.

BioMarin Pharmaceutical Inc. (BMRN) vs Globus Medical, Inc. (GMED)

A side-by-side comparison of BioMarin Pharmaceutical Inc. and Globus Medical, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BMRN

BioMarin Pharmaceutical Inc.

$11.12B

$57.54HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

GMED

Globus Medical, Inc.

$10.33B

$76.57HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — BMRN vs GMED

growth of $100 · dividends reinvested · last 10y

BMRN -39.5% (-4.9%/yr)GMED +228.5% (+12.6%/yr)GMED compounded faster over this window

Log scale — wide-divergence pair

BMRN GMED

BMRN vs GMED: by the numbers

•BMRN is the larger company ($11.12B vs $10.33B market cap).
•GMED trades at the lower trailing earnings multiple (19.68 vs 147.54 P/E), one valuation lens rather than an overall verdict.
•GMED converts more revenue to profit (17.03% vs 2.14% net margin).
•GMED grew revenue faster over the past five years (27.65% vs 12.19% CAGR).

Metrics side by side

Valuation

Metric	BMRN	GMED
P/E ratio	147.54	19.68
Forward P/E	N/A	15.31
PEG ratio	N/A	0.63
P/S ratio	3.26	3.28
P/B ratio	1.76	2.17
EV / EBITDA	33.90	10.64
FCF yield	6.59%	7.27%

Profitability

Metric	BMRN	GMED
Gross margin	75.55%	68.55%
Operating margin	16.56%	20.75%
Net margin	2.14%	17.03%
ROE	1.15%	11.23%
ROIC	1.40%	10.49%

Growth (annualized)

Metric	BMRN	GMED
Revenue CAGR (5Y)	12.19%	27.65%
EPS CAGR (5Y)	-17.46%	30.79%
FCF CAGR (5Y)	33.84%	29.93%
Total return CAGR (5Y)	-5.59%	-0.44%

Frequently asked

Which has the lower trailing P/E, BMRN or GMED?: GMED has the lower trailing P/E: BMRN trades at 147.54 and GMED at 19.68. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BMRN or GMED?: Over the past five years, GMED grew revenue faster — BMRN at a 12.19% CAGR versus GMED at 27.65%.
Is BMRN or GMED more profitable?: GMED runs the higher net margin — BMRN at 2.14% versus GMED at 17.03%.
How have BMRN and GMED total returns compared?: Over the past 10 years, BMRN delivered -4.98% and GMED delivered 12.82% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BMRN analysis Full GMED analysis Interactive comparison tool

Dig into the metrics

BioMarin Pharmaceutical P/E ratio Globus Medical P/E ratio BioMarin Pharmaceutical ROE Globus Medical ROE BioMarin Pharmaceutical operating margin Globus Medical operating margin BioMarin Pharmaceutical revenue growth Globus Medical revenue growth BioMarin Pharmaceutical free cash flow Globus Medical free cash flow

BioMarin Pharmaceutical & Globus Medical appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.